Lysosomal glycogen storage induced by Acarbose, a 1,4-alpha-glucosidase inhibitor.
The 1,4-alpha-glucosidase inhibitor. Acarbose, when injected intraperitoneally disturbs liver lysosome metabolism, causing distinct and persistent inhibition of the enzymes and acute disturbances of lysosomal glycogen metabolism. A feedback control mechanism appears to operate, affecting cytosolic carbohydrate metabolism. A model is suggested for the adult form of lysosomal storage disease. The biochemical effects closely resemble those occurring in glycogenosis type II (Pompe's disease), and these have been confirmed by electron microscopy.
D020909:Acarbose; D000818:Animals; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D008099:Liver / Q000187:drug effects / Q000648:ultrastructure; D008112:Liver Glycogen / Q000378:metabolism*; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D009844:Oligosaccharides / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014312:Trisaccharides / Q000494:pharmacology*
D065089:Glycoside Hydrolase Inhibitors; D008112:Liver Glycogen; D009844:Oligosaccharides; D014312:Trisaccharides; D005959:Glucosidases; D020909:Acarbose